Real-World Studies
Regorafenib Efficacy and Safety in Second-Line vs Later-Line Advanced Hepatocellular Carcinoma
Tak et alTargeted Oncology
A multicenter real-world study evaluated the efficacy and safety of regorafenib as second-line versus later-line therapy in 255 patients with advanced hepatocellular carcinoma (HCC), incorporating an exploratory analysis of prior immune checkpoint inhibitor (ICI) exposure. Among the enrolled cohort, 209 patients received second-line regorafenib and 46 received later-line therapy. Overall, patients achieved an objective response rate (ORR) of 11.0% and a disease control rate (DCR) of 39.2%.
No statistically significant differences were observed between second-line and later-line cohorts regarding ORR, DCR, median overall survival (OS), progression-free survival (PFS), or time to progression. Furthermore, prior ICI exposure within the later-line subgroup did not significantly influence OS or PFS.
Regarding safety and tolerability, the mean maintained dose of regorafenib was significantly lower in the later-line group compared to the second-line group. Discontinuation attributed to adverse events and liver dysfunction occurred more frequently in later-line patients, whereas discontinuation due to disease progression was less frequent.
The onset of hand-foot skin reaction (HFSR) served as a positive prognostic indicator, with patients experiencing HFSR achieving longer OS and PFS. Patients with Grade 3–4 HFSR demonstrated the best survival outcomes compared to those without HFSR. Additionally, multivariate analysis demonstrated that Child–Pugh class A liver function, smaller tumor size, lower baseline alpha-fetoprotein (AFP) levels, and the absence of portal vein tumor thrombosis independently predicted longer overall survival. The authors note that the lack of significant differences in survival outcomes between treatment lines should be interpreted cautiously due to treatment-selection bias and the relatively small sample size of the later-line subgroup.
Key Takeaways
- In a real-world study of 255 patients with advanced hepatocellular carcinoma, regorafenib achieved an overall objective response rate of 11.0% and a disease control rate of 39.2%, with no significant differences in response rates, median overall survival, or progression-free survival between second-line (n = 209) and later-line (n = 46) therapy.
- Prior exposure to immune checkpoint inhibitors was not significantly associated with overall survival or progression-free survival outcomes among patients receiving regorafenib in later treatment lines.
- Development of hand-foot skin reaction was associated with longer overall and progression-free survival, with Grade 3–4 skin toxicity predicting the best survival outcomes compared with no skin reaction.
Read the original sourceTargeted Oncology
